Glenmark gets USFDA nod for anti-hypertension tablets

Agencies
Posted: Monday, Jun 01, 2009 at 1336 hrs IST
Updated: Monday, Jun 01, 2009 at 1336 hrs IST

Font Size

Feedback

Discuss

GSK Pharma Q3 profit rises 7%Dr Reddy's Q2 net up 3 fold at Rs 240 cr Piramal Healthcare Q2 net up 45 pct Ranbaxy hails US court ruling on Valcyte patent

Mumbai: Glenmark Pharmaceuticals said it has received the final approval from the US drug regulator for the marketing of its anti- hypertension tablets.

Glenmark Generics, a subsidiary firm of the company, has received the final approval from the US Food and Drug Administration (USFDA) for its hydralazine hydrochloride tablets, used for the treatment of hypertension, Glenmark Pharmaceuticals said in a filing to the Bombay Stock Exchange.

The company will immediately commence marketing and shipping its generic version in the US market, it added.

According to an estimate, as on March 2009, the market size of anti-hypertension drugs in the US was over USD 55 million.

Shares of Glenmark Pharma were trading at Rs 227, down 0.04 per cent in afternoon trade on the BSE.

Post Comments

Comments: (Limit 3,000 characters)

Name		Message
Email ID
Subject

TERMS OF USE:
The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).

I agree to the terms of use.

Latest News

Print Edition

Events

Glenmark gets USFDA nod for anti-hypertension tablets

Post Comments